INTERMEDIATE-RISK GROUP FOR DIFFERENTIATED CARCINOMA OF THYROID

被引:0
|
作者
SHAHA, AR
LOREE, TR
SHAH, JP
机构
关键词
D O I
暂无
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. We have previously described prognostic factors in differentiated carcinoma of the thyroid gland relating to age, size and extrathyroid extension of the tumor, histologic grade, gender, and distant metastasis. These factors have identified patients in the low-risk group with excellent prognosis and the high-risk group with significant mortality. However, some patients fall within the intermediate-risk category where due deliberation in decision making is required for selection of appropriate treatment. Methods. A retrospective review of a consecutive series of 1038 previously untreated patients with differentiated carcinoma of thyroid treated during a period of 55 years was undertaken. data gathered from review of the charts were subjected to univariate and multivariate analysis to assess prognostic factors. On the basis of the patient's age, presence of distant metastasis, and size, grade, and histologic characteristics of the tumor they could be classified into low-, intermediate-, and high-risk categories. Thus 403 (39%) patients were in the low-risk group, 232 (22%) patients in the high-risk category, and 403 (39%) patients in the intermediate-risk category. Results. With a median follow-up of 20 years, 99% survival was achieved in the low-risk group, whereas only 57% survived in the high-risk group. Interestingly, in the intermediate-risk category of 403 patients, the 20-year survival was only 85%. Our results clearly identify a distinct intermediate-risk category that includes low-risk patients with high-risk tumor or high-risk patients with low-risk tumor. Conclusion. Patients in the intermediate-risk category should be considered for an aggressive treatment approach based on individual prognostic factors.
引用
收藏
页码:1036 / 1041
页数:6
相关论文
共 50 条
  • [21] DIFFERENTIATED THYROID-CARCINOMA, INTERMEDIATE TYPE
    ADKINS, GF
    HARTLEY, L
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1987, 57 (04): : 275 - 277
  • [22] Pulmonary embolism risk stratification: the intermediate-risk group
    Paiva, Luis
    Barra, Sergio
    Providencia, Rui
    BLOOD COAGULATION & FIBRINOLYSIS, 2013, 24 (08) : 896 - 898
  • [23] Recurrence following hemithyroidectomy in patients with low- and intermediate-risk papillary thyroid carcinoma
    Ahn, D.
    Lee, G. J.
    Sohn, J. H.
    BRITISH JOURNAL OF SURGERY, 2020, 107 (06) : 687 - 694
  • [24] Intermediate-risk urothelial carcinoma: An unresolved problem?
    Pycha, A
    Lodde, M
    Comploj, E
    Negri, G
    Egarter-Vigl, E
    Vittadello, F
    Lusuardi, L
    Palermo, S
    Mian, C
    UROLOGY, 2004, 63 (03) : 472 - 475
  • [25] Postoperative radioactive iodine-131 ablation is not necessary among patients with intermediate-risk differentiated thyroid carcinoma: a population-based study
    Zhang, Hong
    Cai, Yuechang
    Zheng, Li
    Zhang, Zhanlei
    Jiang, Ningyi
    HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2017, 20 (01): : 3 - 10
  • [26] Delayed initial radioiodine therapy related to incomplete response in low- to intermediate-risk differentiated thyroid cancer
    Li, Hui
    Zhang, Ying-qiang
    Wang, Chen
    Zhang, Xin
    Li, Xin
    Lin, Yan-song
    CLINICAL ENDOCRINOLOGY, 2018, 88 (04) : 601 - 606
  • [27] Patient Preference in Physician Decision-Making for Patients With Low- to Intermediate-Risk Differentiated Thyroid Cancer
    Schumm, Max A.
    Shu, Michelle L. L.
    Leung, Angela M.
    Livhits, Masha J.
    Yeh, Michael W. W.
    Sacks, Greg D.
    Wu, James X. X.
    JAMA SURGERY, 2023, 158 (08) : 886 - 888
  • [28] The role of routine diagnostic radioiodine whole-body scintigraphy in patients with intermediate-risk differentiated thyroid cancer
    Jeong, Shin Young
    Kim, Do-Hoon
    Hong, Chae Moon
    Kim, Hae Won
    Lee, Sang-Woo
    Ahn, Byeong-Cheol
    Lee, Jaetae
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [29] Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer
    Hartl, Dana M.
    Guerlain, Joanne
    Breuskin, Ingrid
    Hadoux, Julien
    Baudin, Eric
    Al Ghuzlan, Abir
    Terroir-Cassou-Mounat, Marie
    Lamartina, Livia
    Leboulleux, Sophie
    CANCERS, 2020, 12 (11) : 1 - 18
  • [30] Intermediate-Risk Group in Patients with Transitional Cell Carcinoma of the Bladder: Prediction of High-Risk Patients in This Heterogeneous Group
    Yencilek, F.
    Onal, B.
    Erozenci, A.
    Talat, Z.
    Ataus, S.
    UROLOGIA INTERNATIONALIS, 2009, 83 (03) : 295 - 299